OTIPRIO™ ciprofloxacin otic suspension 6%

OTO-104

A sustained-exposure formulation of the steroid dexamethasone that is in two Phase 3 clinical trials for patients with Ménière's disease...
LEARN MORE »

OTO-311

A sustained-exposure formulation of the NMDA receptor antagonist gacyclidine for the treatment of tinnitus that is in a Phase 1 clinical safety trial...
LEARN MORE »

OTO-4XX

Otonomy has acquired the rights to multiple product candidates for our fourth development program, which will target age-related hearing loss, also known as presbycusis....
LEARN MORE »